Regeneron Soars 5.05% on FDA Wins: Is This the Start of a New Bull Run?

Summary
• Regeneron Pharmaceuticals (REGN) surges 5.05% to $737.29, hitting an intraday high of $753.51
• FDA approvals for Eylea HD and Libtayo drive optimism in the biotech sector
• Options volume spikes as traders bet on continued momentum
• Turnover jumps 1.54% amid heightened volatility

Regeneron’s explosive move has captured market attention, fueled by regulatory wins and a bullish technical setup. With the stock trading near its 52-week high of $800.99, investors are weighing whether this is a breakout or a correction. The FDA’s recent approvals for higher-dose Eylea and expanded Libtayo use have ignited short-term optimism, while technical indicators suggest a continuation of the upward trend.

FDA Approvals Fuel Regeneron's Surge
Regeneron’s 5.05% intraday rally is directly tied to two critical FDA approvals. First, the agency greenlit Eylea HD (aflibercept) for monthly dosing in macular edema and retinal vein occlusion, enhancing its competitive edge against biosimilars. Second, Libtayo (cemiplimab) received EU approval for adjuvant treatment of high-risk cutaneous squamous cell carcinoma, expanding its oncology footprint. These regulatory milestones validate Regeneron’s R&D pipeline and reinforce its market leadership in ophthalmology and immuno-oncology, driving immediate buying pressure.

Options Playbook: Capitalizing on Regeneron's Volatility
• MACD: 30.56 (above signal line 25.66), RSI: 65.76 (neutral), Bollinger Bands: Upper $737.25 (near current price), 200D MA: $595.56 (well below)
• Key Levels: Support at $651.59 (30D), resistance at $740 (immediate)
• Short-Term Outlook: Bullish continuation expected as RSI remains below overbought (70) and MACD histogram expands
Top Options Contracts:
• REGN20251128C740
- Call, Strike $740, Expiry 2025-11-28
- IV: 30.52% (moderate), Leverage: 55.06% (high), Delta: 0.493 (moderate), Theta: -2.236 (strong time decay), Gamma: 0.0113 (responsive to price swings), Turnover: $140,219 (liquid)
- Why: High leverage and moderate delta position this call to capitalize on a 5% upside (target $774.15), with gamma ensuring sensitivity to further gains.
• REGN20251128C750
- Call, Strike $750, Expiry 2025-11-28
- IV: 30.71% (moderate), Leverage: 79.34% (very high), Delta: 0.384 (moderate), Theta: -1.891 (strong time decay), Gamma: 0.0107 (responsive), Turnover: $60,875 (liquid)
- Why: Aggressive bulls should target this contract for maximum leverage (79.34%) if the stock breaks above $750, with theta ensuring decay cushions against minor pullbacks.
Payoff Estimate: At a 5% upside ($774.15), the REGN20251128C740 yields $34.15 per contract, while the REGN20251128C750 nets $24.15. Both contracts offer asymmetric risk/reward for a bullish stance. Aggressive bulls may consider REGN20251128C750 into a breakout above $750.

Backtest Regeneron Stock Performance
We detected one date (2024-06-06) from 2022-01-01 to 2025-11-20 on which REGN.O closed ≥ 5 % above its prior-day close. The event study shows the average performance after that surge.Key take-aways• Short-term drift: the stock kept rising—median event return reached ≈ 7 % by day 12 and peaked near 10 % at day 24.• Consistent positive bias: win rate stayed at 100 % throughout the 30-day window for this single observation; however, the sample size is obviously too small to claim statistical significance.• Benchmark-adjusted alpha: REGN outperformed the market by roughly +9 % at the 24-day peak.Given only one qualifying event, statistical power is limited. If you would like to loosen the trigger (e.g., 4 % surge, intraday not close-to-close, or extend the look-back further) we can rerun the test.Below is an interactive panel with the full event-study curves and table.Feel free to explore the chart and let me know if you’d like to adjust parameters or test additional conditions.

Act Now: Regeneron's Breakout Could Be Just the Beginning
Regeneron’s 5.05% surge is underpinned by regulatory wins and a technically robust setup, suggesting the move could extend toward its 52-week high of $800.99. Traders should monitor the $740 support-turned-resistance level and RSI for overbought signals (70+). Meanwhile, sector leader Johnson & Johnson (JNJ) remains flat at +0.12%, indicating Regeneron’s move is product-specific rather than sector-driven. For those seeking entry, the REGN20251128C750 offers high leverage if the stock breaks above $750. Position now—this is a high-conviction trade for the next 10 days.